12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Company News  |  Deals

Asuragen, Becton Dickinson deal

Asuragen granted Becton Dickinson non-exclusive, worldwide rights to Asuragen's Armored RNA technology for use in in vitro diagnostic...

Read the full 66 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >